Erratum to: Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor

被引：0
|
作者：
Henri Bounameaux
A. John Camm
机构：
[1] University Hospital of Geneva,Department of Internal Medicine
[2] University Medical Center (CMU),Faculty of Medicine, Dean’s Office
[3] St George’s University of London,Division of Clinical Sciences
来源：
Drugs | 2014年 / 74卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1455 / 1455
相关论文
共 50 条
  • [41] The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
    Perzborn, Elisabeth
    Roehrig, Susanne
    Straub, Alexander
    Kubitza, Dagmar
    Misselwitz, Frank
    NATURE REVIEWS DRUG DISCOVERY, 2011, 10 (01) : 61 - +
  • [42] The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
    Elisabeth Perzborn
    Susanne Roehrig
    Alexander Straub
    Dagmar Kubitza
    Frank Misselwitz
    Nature Reviews Drug Discovery, 2011, 10 : 61 - 75
  • [43] Pharmacokinetics and Pharmacodynamics of Rivaroxaban - An Oral, Direct Factor Xa Inhibitor
    Kreutz, Reinhold
    CURRENT CLINICAL PHARMACOLOGY, 2014, 9 (01): : 75 - 83
  • [44] Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict
    Carreiro, Jennifer
    Ansell, Jack
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (12) : 1937 - 1945
  • [45] Successful Treatment With the Oral Factor Xa Inhibitor Edoxaban in Heparin-Induced Thrombocytopenia With Thrombosis
    Porres-Aguilar, Mateo
    Najera, Carolina
    Mares, Adriana C.
    Benzidia, Ilham
    Prakash, Swathi
    Crichi, Benjamin
    ANGIOLOGY, 2023,
  • [46] Melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, nor heparin aggravates tissue factor-induced hypercoagulation in rats
    Furugohri, Taketoshi
    Fukuda, Toshio
    Tsuji, Naoki
    Kita, Akemi
    Morishima, Yoshiyuki
    Shibano, Toshiro
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2012, 686 (1-3) : 74 - 80
  • [47] Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement
    Raskob, Gary
    Cohen, Alexander T.
    Eriksson, Bengt I.
    Puskas, David
    Shi, Minggao
    Bocanegra, Tomas
    Weitz, Jeffrey I.
    THROMBOSIS AND HAEMOSTASIS, 2010, 104 (03) : 642 - 649
  • [48] A Thorough Electrocardiogram Study of Edoxaban, a Novel Factor Xa Inhibitor
    Mendell, J.
    Basavapathruni, R.
    Swearingen, D.
    Draves, A.
    Zhang, G.
    Morganroth, J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (08): : 1241 - 1246
  • [49] Assessment of factor Xa chromogenic assays for measuring the pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor
    Perzborn, E.
    Hardwardt, M.
    Samama, M. M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 379 - 380
  • [50] Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment
    Jochen Graff
    Sebastian Harder
    Clinical Pharmacokinetics, 2013, 52 : 243 - 254
12345